Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 49 out of 100. Costs and economics

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

BackgroundSeveral monoclonal antibodies designed to slow cognitive and functional decline in individuals with early Alzheimer's disease (AD) have been recently approved. However, a comprehensive evaluation of the cost-effectiveness of all FDA-approved neurotherapeutic agents for AD remains lacking.ObjectiveThis study aimed to systematically review and analyze the incremental costs and effectiveness of currently available FDA-approved neurotherapeutic agents for AD to provide consolidated evidence on their economic value.MethodsA systematic review was conducted across PubMed, Embase, Cochrane CENTRAL, and Web of Science, adhering to the Consolidated Health Economic Evaluation Reporting Standards (CHEERS) and PRISMA guidelines.ResultsTwenty-three articles were included. Most studies (74%) used a Markov model. Nearly half (48%) of studies were analyzed from both healthcare system and societal perspectives. Industry-funded studies made up 43%, while 39% were funded by non-profits, and 17% received no funding. Quality-adjusted life year (QALY) was the most common effectiveness measure (91%). At a willingness-to-pay (WTP) threshold of $100,000/QALY, all studies found memantine cost-effective, and more than half reported cost-effectiveness for donepezil, rivastigmine, and galantamine. Aducanumab, lecanemab, and donanemab were not cost-effective in any study. Under the WTP threshold of $150,000/QALY, value-based prices for aducanumab, lecanemab, and donanemab were estimated below $5,960, $15,700, and $33,700, respectively.ConclusionsTraditional symptom-targeting drugs were consistently cost-effective, whereas anti-amyloid therapies were not. Future independent cost-effectiveness analyses would benefit from head-to-head comparisons using real-world data and greater attention to disparities in dementia research.

What this study adds

Evidence grade: Moderate

This is a pooled review. At a willingness-to-pay threshold of $100,000 per QALY, all included studies found memantine cost-effective and more than half reported cost-effectiveness for donepezil, rivastigmine and galantamine, while aducanumab, lecanemab and donanemab were not cost-effective in any study. These conclusions come from economic models, not from new trials of whether these drugs work.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Jiang, X., Lv, G., Xiong, X., Yuan, J., & Kevin Lu, Z. (2026). Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review. Journal of Alzheimer's Disease. https://doi.org/10.1177/13872877261430376

Vancouver

Jiang X, Lv G, Xiong X, Yuan J, Kevin Lu Z. Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review. Journal of Alzheimer's Disease. 2026. doi:10.1177/13872877261430376. PMID: 41837605.

BibTeX

@article{jiang2026-41837605,
  author  = {Jiang, X. and Lv, G. and Xiong, X. and Yuan, J. and Kevin Lu, Z.},
  title   = {{Cost-effectiveness of traditional and novel neurotherapeutic agents for Alzheimer's disease: A systematic review}},
  journal = {Journal of Alzheimer's Disease},
  year    = {2026},
  doi     = {10.1177/13872877261430376},
  pmid    = {41837605},
  url     = {https://doi.org/10.1177/13872877261430376}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

At a willingness-to-pay threshold of $100,000 per QALY, all included studies found memantine cost-effective and more than half reported cost-effectiveness for donepezil, rivastigmine and galantamine, while aducanumab, lecanemab and donanemab were not cost-effective in any study. These conclusions come from economic models, not from new trials of whether these drugs work.

Study details

How this study scored 49/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 12 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 2 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year 0 of 6; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record left out, no data; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read left out, no data. 46 of the 94 points it could be judged on, which is 49 of 100. Total 49 of 100.46 of the 94 points we could judge = 49 of 100

Published in a peer-reviewed journal, and it is a systematic review of all the studies on the question. Scored zero for sample size and studied in people because the record does not state it. We have no data on senior author's track record and free to read, so those were left out: it earned 46 of the 94 points we could judge it on, which is 49 out of 100.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Alzheimer's Disease)
Journal's citation record 2 / 4 Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29)
Study design 12 / 12 A systematic review of all the studies on the question
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 2 / 3 Effect reported as a number, without an interval or test
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 A review of other studies — randomization is not credited here
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 2 year(s) since 2026
Impact for its field and year 0 / 6 Cited 0.0× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record — / 4 OpenAlex's profile for last-listed author Z. Kevin Lu holds only 9 work(s), too few to judge a track record — left out of this score
Institution's track record 1 / 3 University of Cincinnati: institution h-index 918 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 4 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41837605)
Free to read — / 2 Access not recorded — left out of this score
Points 46 / 94 Scored on 18 of 20 parts. We have no data for the rest, so they are left out: 46 of the 94 points we could judge it on is 49 out of 100.
Total 49 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Related studies in Costs and economics from nearby years

Also in Costs and economics

21 studies in the library are filed under Costs and economics with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Costs and economics hub.

Similar studies

More on Costs and economics

See all studies in Costs and economics →